Bristol Myers Squibb has secured a major regulatory win as the FDA approves its cancer drug for stage IV. The drug, Opdivo (nivolumab) is for patients with advanced classical Hodgkin lymphoma, marking a shift in how the disease is treated...
.png "Sun Pharma Launches Semaglutide Injection in India; Boosts Drug Access")
Sun Pharmaceutical Industries Limited has rolled out its semaglutide injection in India under the brands Noveltreat and Sematrinity, widening access to treatments for type 2 diabetes and chronic weight management.
Glenmark Pharmaceuticals has launched its new diabetes drug, Glipiq, in India, with a clear focus on making advanced treatment more affordable and accessible. The move comes as the country continues to see a sharp rise in type 2 diabetes, placin...
The Union Ministry of Health and Family Welfare has stepped up efforts to tackle HIV/AIDS in India by focusing on stronger action at the district level. As part of this initiative, the Suraksha Sankalp Karyashala was recently held in Delhi, brin...
Indian Pharma Companies have kicked off an aggressive race in generic semaglutide after the patent for the blockbuster diabetes and weight-loss drug expired on March 20, 2026.
India’s pharmaceutical and medtech sectors are rapidly transforming into a global force, creating new opportunities for the nation’s economy. Union Minister Dr. Jitendra Singh said today that the country is steadily evolving...
India’s push to lead in gene therapy clinical progress took center stage in Parliament today as officials from the government detailed how the country is advancing cutting edge treatments while relying on a firm regulatory system.
Lupin Manufacturing Solutions announces the expansion of its Dabhasa facility to enhance peptide and CRDMO capabilities, supporting global demand for complex therapeutics and drug development.
.png "Natco's Affordable Semaglutide Shakes India's Drug Market at INR 1,290")
Natco Pharma has just shaken up the India’s diabetes drug market with its launch of semaglutide at just INR 1,290 a month, making high end diabetes treatment far more affordable for millions.
Tata Elxsi and Terumo Corporation have launched the Terumo–Tata Elxsi Offshore Development Centre to strengthen global support for cardiac and vascular solutions.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")